YCYau-Lam Alex Chau

Yau-Lam Alex Chau

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Yau-Lam Alex Chau has a total of 13 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Esmolol in the management of refractory ventricular fibrillation: a systematic review and meta-analysis

    by Kathleen Lau, Yau-Lam Alex Chau, Ting-An Cheng, Michael Lai, David Seonguk Yeom, Ursula Ellis, Anthony Lau

    Background: Refractory ventricular fibrillation (rVF) presents a significant challenge in advanced cardiovascular life support (ACLS), with traditional antiarrhythmics showing limited success in improving long-term survival and neurological function. Esmolol, a beta-1 selective adrenergic receptor antagonist, might offer benefits due to its rapid onset and catecholamine-suppressing effects during cardiac arrest.Methods: This systematic review and meta-analysis (SRMA) evaluates the effectiveness of esmolol in improving the temporary return of spontaneous circulation (ROSC), sustained ROSC, survival to discharge, and survival to discharge with favorable neurological outcomes in rVF patients. This SRMA reviewed Medline (Ovid), Embase (Ovid), and Cochrane Central (Ovid) from their inception until October 2, 2025, for full-text clinical or observational studies assessing esmolol use alongside standard ACLS in adult rVF in both prehospital and in-hospital settings.Results: The risk of bias was independently assessed using the Newcastle-Ottawa Scale. Pooled risk ratios (RRs; 95% CI) are reported. Analyses in which I² >50% used a random-effects model; otherwise, a common-effect model was used. Four studies (n=273) are included. Esmolol was associated with an increased temporary ROSC (RR, 1.80; 95% CI, 1.09–2.98), and although the links were not statistically significant, esmolol trended toward a benefit in sustained ROSC (RR, 1.25; 95% CI, 0.28–5.66), survival to discharge (RR, 1.08; 95% CI, 0.57–2.03), and survival to discharge with favorable neurological outcomes (RR, 2.08; 95% CI, 0.83–5.24).Conclusions: Esmolol was associated with improved temporary ROSC in rVF. The sensitivity analysis suggests potential benefits for sustained ROSC and neurological survival, but more data are needed. Further research is needed to clarify its role.

  • Open Access

    Developing a SNOMED CT-based value set to document symptoms and diagnoses for adverse drug events: A mixed-methods study (Preprint)

    by Erica Lau, Linda Bird, Anthony Lau, Yau-Lam Alex Chau, Katherine Butcher, Susan Buchkowsky, Kira Gossack-Keenan, Cheryl Sadowski, Corinne Hohl

    Journal of Medical Internet Research - International Scientific Journal for Medical Research, Information and Communication on the Internet #Preprint #PeerReviewMe: Warning: This is a unreviewed preprint. Readers are warned that the document has not been peer-reviewed by expert/patient reviewers or an academic editor, may contain misleading claims, and is likely to undergo changes before final publication, if accepted, or may have been rejected/withdrawn. Readers with interest and expertise are encouraged to sign up as peer-reviewer, if the paper is within an open peer-review period. Please cite this preprint only for review purposes or for grant applications and CVs (if you are the author). Background: Adverse drug events (ADE) lead to over two million emergency department visits in Canada annually, resulting in significant patient harm and over $1 billion in healthcare costs. Effective documentation and sharing of ADE information through electronic medical records (EMRs) is essential to inform subsequent care and improve safety when culprit medications can be replaced and re-exposures avoided. Yet current systems often lack standardized comprehensive ADE value sets. Objective: This study aimed to develop a SNOMED CT value set for symptoms and diagnoses to standardize ADE documentation and improve ADE data integration into EMRs. Methods: We used ADE data from ActionADE, a prospective reporting system implemented in nine hospitals in British Columbia. We extracted 5,792 reports that yielded 827 unique ADE symptom and diagnosis terms based on MedDRA preferred terms. Two independent mappers employed both automated and manual mapping approaches to match these terms to SNOMED CT concepts. Two clinical experts conducted validation, followed by a quality assurance review by a separate clinical team. Discrepancies were resolved through consensus discussions. Interrater reliability was assessed using Cohen’s kappa. Results: The automated mapping process identified 63.8% (528/827) semantically equivalent matches from SNOMED CT’s Clinical Finding hierarchy. Two mappers manually reviewed the automatically mapped terms and identified appropriate target concepts for the unmapped terms. After the manual mapping process, 95.3% (788/827) of the source terms were successfully mapped to SNOMED CT concepts, with 4.7% (39/827) remaining unmapped. Interrater reliability between the mappers was strong (κ = 0.87, 95% CI: 0.85-0.89). The validation phase identified and removed one irrelevant term, resulting in 98.9% (778/826) terms mapped, with 1.6% (9/826) unmapped, and a high interrater reliability (κ = 0.88, 95% CI: 0.80-0.95). During quality assurance, six terms were flagged for concerns regarding clinical relevance or safety risks and were resolved through discussions. The final value set comprised 813 SNOMED CT concepts, with 95.0% of terms classified as semantically equivalent. Thirteen additional terms remained unmapped and will be reviewed as new SNOMED CT codes are added. Conclusions: This study developed a SNOMED CT-based value set to document symptoms and diagnoses for adverse drug events observed in adults in EMRs. Adopting this value set can improve the consistency, accuracy, and interoperability of ADE documentation in EMRs, helping to reduce repeat ADEs and enhance patient safety. Ongoing refinement and improved clinical usability are essential for its widespread adoption. Future research should assess the impact of integrating this value set into EMRs on ADE reporting, pharmacovigilance, and patient safety outcomes.